BioCentury | Aug 28, 2014
Distillery Therapeutics

Indication: Neurology

...include testing DP1 inhibitors in the mouse model of ALS. Merck & Co. Inc.'s Cordaptive (MK-0524A...
...testing for atherosclerosis and cardiovascular disease. Merck also has MK-0524B, an extended-release, fixed-dose combination of MK-0524A...
BioCentury | Aug 28, 2014
Targets & Mechanisms

A cultured approach to ALS therapy

...to be well tolerated in humans," Anthony said. In 2008, Merck & Co Inc. 's Tredaptive...
...Tredaptive, preclinical studies showed that the drug had no CNS exposure. In 2013, Merck withdrew Tredaptive...
BioCentury | Oct 14, 2013
Strategy

Reviving Merck

...than 3,000 patients. In December 2012, Merck said it would not seek U.S. approval of Tredaptive...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...Merck & Co. Inc. (NYSE:MRK) Says it will suspend the worldwide availability of cardiovascular drug Tredaptive...
BioCentury | Mar 18, 2013
Clinical News

Tredaptive: Additional Phase III data

...endpoint of coronary death, non-fatal MI, stroke or revascularization occurred in 13.2% of patients receiving Tredaptive...
...and Trevaclyn in Italy and Portugal. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive...
...Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive , Pelzont , Trevaclyn ( MK-0524A...
BioCentury | Jan 28, 2013
Clinical News

Tredaptive regulatory update

...confirmed a recommendation from the agency's Pharmacovigilance Risk Assessment Committee to suspend marketing authorization of Tredaptive...
...product as Tredaptive and Cordaptive in about 40 countries and as Pelzont in Italy and Trevaclyn...
...Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive , Pelzont , Trevaclyn ( MK-0524A...
BioCentury | Jan 14, 2013
Clinical News

Tredaptive regulatory update

...Merck said it will suspend the worldwide availability of Tredaptive after data from the investigator-led Phase...
...product as Tredaptive and Cordaptive in about 40 countries and as Pelzont in Italy and Trevaclyn...
...Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive , Pelzont , Trevaclyn ( MK-0524A...
BioCentury | Jan 12, 2013
Company News

Merck pulling CV drug Tredaptive

...Merck & Co. Inc. (NYSE:MRK) said it will suspend the worldwide availability of Tredaptive . The...
...non-fatal serious adverse events. Separately, EMA's Pharmacovigilance Risk Assessment Committee recommended suspending marketing authorization of Tredaptive...
...reviewing Tredaptive in December following the HPS2-THRIVE data (see BioCentury Extra, Dec. 21, 2012) . Tredaptive...
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

...to treat non-infectious uveitis Merck & Co. Inc. (NYSE:MRK) Will not seek U.S. approval for Tredaptive...
BioCentury | Dec 24, 2012
Clinical News

Tredaptive: Phase III data

...Phase III HPS2-THRIVE trial in 25,673 patients at high risk for cardiovascular events showed that Tredaptive...
...product as Tredaptive and Cordaptive in about 40 countries and as Pelzont in Italy and Trevaclyn...
...in January. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tredaptive , Cordaptive ( MK-0524A...
Items per page:
1 - 10 of 52